# Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

> **NCT03196206** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 24 (actual)

## Conditions studied

- Thrombosis

## Interventions

- **DRUG:** BMS-986177

## Key facts

- **NCT ID:** NCT03196206
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-13
- **Primary completion:** 2018-03-04
- **Final completion:** 2018-03-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03196206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03196206, "Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03196206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*